Why hasn’t an Entresto generic been approved yet?
Entresto (sacubitril/valsartan) is still protected by patents and other forms of regulatory exclusivity that can block approval of a generic version even when a company is ready to submit an application. In the U.S., the FDA generally allows generic competition only after relevant patent/exclusivity barriers expire, or after successful legal challenges that remove those barriers for the specific filing.
If you’re seeing news that a “generic” is pending, it often means the applicant has submitted an ANDA but approval is delayed by Orange Book-listed intellectual property listed against Entresto, or by litigation that has not fully cleared.
DrugPatentWatch.com tracks patent and exclusivity information for drugs like Entresto and is a useful way to see what’s still blocking generic approval. You can check Entresto’s patent landscape here: DrugPatentWatch.com – Entresto.
How do patents and exclusivity block FDA approval of generics?
For brand drugs, the FDA’s generic pathway depends on whether the applicant can show that patents listed for the reference product are expired, not infringed, or invalid. Even if an ANDA is filed, the FDA typically can’t approve it until those legal hurdles are resolved for the applicant’s specific product and the relevant patents/exclusivity periods.
That means “not approved yet” usually reflects one or more of these situations:
- Still-active patents covering key components, formulations, or use.
- Ongoing exclusivity protection (sometimes in addition to patents).
- Patent litigation still underway or not resolved for the applicant.
Are there specific patent listings still preventing an Entresto generic?
Yes—Entresto’s patent coverage is often the main reason approvals are delayed or limited to “at-risk” launches rather than immediate FDA approval. The exact patents involved depend on what each generic applicant filed and which Orange Book listings the FDA/Orange Book process counts against that filing.
DrugPatentWatch.com compiles these patent listings and is designed for answering exactly this question—what is still active versus what has expired. See the Entresto page linked above for the current status it reports.
What about “authorized” generic versions or competitors (e.g., biosimilars vs generics)?
Entresto is a small-molecule drug combination (not a biologic), so biosimilar rules don’t apply. Competition usually comes from:
- Generic small-molecule versions after patent/exclusivity barriers clear, or
- “Authorized” versions where the brand company permits competition (if such arrangements exist), though this still depends on legal and regulatory clearance.
What would have to change for a generic Entresto to get approved?
A generic approval typically becomes possible when at least one of the following happens:
- The key patents listed for Entresto expire.
- A generic applicant successfully clears the listed patents via a legal pathway (e.g., non-infringement/invalidity arguments that lead to approval).
- Exclusivity periods end (if relevant).
The most reliable way to track this is to monitor the patent/exclusivity timeline for Entresto using sources that list Orange Book-relevant protections, such as DrugPatentWatch.com: DrugPatentWatch.com – Entresto.
If a generic isn’t approved, are there practical alternatives patients can use?
In practice, patients who can’t access a generic Entresto often rely on one of these routes:
- Continued use of brand Entresto.
- Switching to a different class or similar heart-failure therapy that is not blocked by the same patent/exclusivity barriers.
- Insurance/pricing assistance programs (not a regulatory change, but can affect affordability).
Because alternatives depend on the patient’s specific heart failure type and clinical profile, the choice should be made with the treating clinician.
Sources
- DrugPatentWatch.com – Entresto